Applying the retro-enantio approach to obtain a peptide capable of overcoming the blood-brain barrier.

The blood-brain barrier (BBB) is a formidable physical and enzymatic barrier that tightly controls the passage of molecules from the blood to the brain. In fact, less than 2 % of all potential neurotherapeutics are able to cross it. Here, by applying the retro-enantio approach to a peptide that targets the transferrin receptor, a full protease-resistant peptide with the capacity to act as a BBB shuttle was obtained and thus enabled the transport of a variety of cargos into the central nervous system.

[1]  E. Giralt,et al.  Retro‐Enantio N‐Methylated Peptides as β‐Amyloid Aggregation Inhibitors , 2009, ChemMedChem.

[2]  Michel Demeule,et al.  Identification and Design of Peptides as a New Drug Delivery System for the Brain , 2008, Journal of Pharmacology and Experimental Therapeutics.

[3]  T. Terasaki,et al.  Fluids and Barriers of the Cns , 2022 .

[4]  Ernest Giralt,et al.  Delivery of gold nanoparticles to the brain by conjugation with a peptide that recognizes the transferrin receptor. , 2012, Biomaterials.

[5]  W. Jefferies,et al.  Transferrin receptor on endothelium of brain capillaries , 1984, Nature.

[6]  Li Di,et al.  High throughput artificial membrane permeability assay for blood-brain barrier. , 2003, European journal of medicinal chemistry.

[7]  E. Gil,et al.  Quaternary ammonium beta-cyclodextrin nanoparticles for enhancing doxorubicin permeability across the in vitro blood-brain barrier. , 2009, Biomacromolecules.

[8]  N. Plesnila,et al.  In vivo temporal and spatial profile of leukocyte adhesion and migration after experimental traumatic brain injury in mice , 2013, Journal of Neuroinflammation.

[9]  E. Giralt,et al.  Shuttle-mediated drug delivery to the brain. , 2011, Angewandte Chemie.

[10]  A. Paillard,et al.  Influence of surface charge and inner composition of porous nanoparticles to cross blood-brain barrier in vitro. , 2007, International journal of pharmaceutics.

[11]  Takashi Suzuki,et al.  Quantitative targeted absolute proteomics of human blood–brain barrier transporters and receptors , 2011, Journal of neurochemistry.

[12]  Shabana I. Khan,et al.  Transport of decursin and decursinol angelate across Caco-2 and MDR-MDCK cell monolayers: in vitro models for intestinal and blood-brain barrier permeability. , 2007, Planta medica.

[13]  P. Gaillard,et al.  2B-Trans technology: targeted drug delivery across the blood-brain barrier. , 2008, Methods in molecular biology.

[14]  C. Ringbom,et al.  Establishment and functional characterization of an in vitro model of the blood-brain barrier, comprising a co-culture of brain capillary endothelial cells and astrocytes. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[15]  Pilar López-Larrubia,et al.  Engineering biofunctional magnetic nanoparticles for biotechnological applications. , 2010, Nanoscale.

[16]  Morteza Malakoutikhah,et al.  Schleuservermittelter Transport von Wirkstoffen ins Gehirn , 2011 .

[17]  Cao Xie,et al.  Retro-inverso isomer of Angiopep-2: a stable d-peptide ligand inspires brain-targeted drug delivery. , 2014, Molecular pharmaceutics.

[18]  J. Tillement,et al.  Drug Transfer Across the Blood‐Brain Barrier: Correlation Between In Vitro and In Vivo Models , 1992 .

[19]  J. Connor,et al.  Regulation of the Profile of Iron-Management Proteins in Brain Microvasculature , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[20]  Maxime Culot,et al.  An in vitro blood-brain barrier model for high throughput (HTS) toxicological screening. , 2008, Toxicology in vitro : an international journal published in association with BIBRA.

[21]  R. Béliveau,et al.  Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier. , 2002, Vascular pharmacology.

[22]  Michel Demeule,et al.  High transcytosis of melanotransferrin (P97) across the blood–brain barrier , 2002, Journal of neurochemistry.

[23]  A. Boer,et al.  Drug Delivery to the Brain by Internalizing Receptors at the Blood‐Brain Barrier , 2007 .

[24]  E. Giralt,et al.  Convergent Synthesis of Repeating Peptides (Val-X-Leu-Pro-Pro-Pro)(8) Adopting a Polyproline II Conformation. , 1996, The Journal of organic chemistry.

[25]  T. Horibe,et al.  A novel transferrin receptor-targeted hybrid peptide disintegrates cancer cell membrane to induce rapid killing of cancer cells , 2011, BMC Cancer.